全身性エリテマトーデス/ループス腎炎治療薬の世界市場予測および分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 16
1.2 List of Figures 22

2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25

3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 28
3.2 Prognosis 29
3.3 Quality of Life 29
3.4 Symptoms 30

4 Epidemiology 31
4.1 Risk Factors and Comorbidities 31
4.1.1 Women are at a higher risk of developing SLE than men 31
4.1.2 Caucasians are at lower risk of developing SLE than other ethnicities 32
4.1.3 Familial history has been associated with an increased risk of developing SLE 33
4.1.4 Certain occupational and environmental exposures trigger SLE 34
4.2 Global Trends 35
4.2.1 US 36
4.2.2 5EU 37
4.2.3 Japan 40
4.3 Forecast Methodology 40
4.4 Sources Used 42
4.4.1 US 42
4.4.2 France 44
4.4.3 Germany 44
4.4.4 Italy 44
4.4.5 Spain 45
4.4.6 UK 45
4.4.7 Japan 46
4.5 Sources Not Used 47
4.5.1 US 47
4.5.2 5EU 47
4.5.3 Japan 48
4.6 Forecast Assumptions and Methods 48
4.6.1 US 49
4.6.2 5EU 49
4.6.3 Japan 52
4.7 Epidemiological Forecast of SLE (2012-2022) 53
4.7.1 Diagnosed Prevalent Cases of SLE 53
4.7.2 Age-Specific Prevalent Cases of SLE 55
4.7.3 Sex-Specific Prevalent Cases of Diagnosed SLE 57
4.7.4 Age-Standardized Prevalence of SLE 58
4.7.5 Diagnosed Prevalent Cases of LN 59
4.7.6 Prevalent Cases of LN, Segmented by Class 61
4.8 Discussion 63
4.8.1 Conclusions on Epidemiology Trends 63
4.8.2 Limitations of the Analysis 64
4.8.3 Strengths of the Analysis 65

5 Disease Management 67
5.1 Diagnosis Overview 67
5.1.1 SLE Diagnosis 67
5.1.2 LN Diagnosis 70
5.2 Treatment Overview 72
5.3 US 76
5.3.1 Diagnosis 76
5.3.2 Clinical Practice 77
5.4 France 79
5.4.1 Diagnosis 79
5.4.2 Clinical Practice 79
5.5 Germany 80
5.5.1 Diagnosis 80
5.5.2 Clinical Practice 81
5.6 Italy 83
5.6.1 Diagnosis 83
5.6.2 Clinical Practice 83
5.7 Spain 84
5.7.1 Diagnosis 84
5.7.2 Clinical Practice 85
5.8 UK 86
5.8.1 Diagnosis 86
5.8.2 Clinical Practice 87
5.9 Japan 88
5.9.1 Diagnosis 88
5.9.2 Clinical Practice 89

6 Competitive Assessment 91
6.1 Overview 91
6.2 Strategic Competitor Assessment 91
6.3 Product Profiles – Major Brands 92
6.3.1 Antimalarial Therapy (numerous brand names) 92
6.3.2 Steroids (numerous brand names) 98
6.3.3 Methotrexate (numerous brand names) 103
6.3.4 Mycophenolate Mofetil (numerous brand names) 107
6.3.5 Cyclophosphamide (numerous brand names) 112
6.3.6 Azathioprine (numerous brand names) 117
6.3.7 Calcineurin Inhibitors (numerous brand names) 121
6.3.8 Benlysta (belimumab) 126
6.3.9 Rituxan (rituximab) 135
6.3.10 Minor Therapeutic Classes 140

7 Opportunity and Unmet Need 142
7.1 Overview 142
7.2 Unmet Needs 143
7.2.1 Efficacious Treatments with Reduced Side Effects 143
7.2.2 Management of LN 144
7.2.3 Improvement in Patients’ Mortality 145
7.2.4 Management of Lupus Comorbidities 146
7.2.5 Sensitive and Reliable Biomarkers 147
7.2.6 Physicians’ Education and Public Awareness of SLE 147
7.2.7 Unmet Needs Gap Analysis 148
7.3 Opportunities 149
7.3.1 Efficacious and Safe Therapies 149
7.3.2 Therapies Targeting LN Patients 150
7.3.3 Treatments for Common Lupus Comorbidities 151
7.3.4 Discovery of Biomarkers 151

8 Pipeline Assessment 152
8.1 Overview 152
8.2 Clinical Trial Mapping 152
8.2.1 Clinical Trials by Therapy Type 152
8.3 Promising Drugs in Clinical Development 153
8.3.1 Blisibimod (A-623) 154
8.3.2 Atacicept 162
8.3.3 Epratuzumab 169
8.3.4 Lupuzor (rigerimod) 177
8.3.5 Orencia (abatacept) 183
8.3.6 Sifalimumab (MEDI-545) 190
8.3.7 PF-04236921 196
8.3.8 Anifrolumab (MEDI-546) 202
8.3.9 Lulizumab Pegol (BMS-931699) 204
8.3.10 BIIB023 206
8.3.11 Voclosporin 208
8.4 Other Drugs in Development 211

9 Current and Future Players 212
9.1 Overview 212
9.2 Trends in Corporate Strategy 214
9.3 Company Profiles 215
9.3.1 GlaxoSmithKline 215
9.3.2 Roche 217
9.3.3 UCB 220
9.3.4 Bristol-Myers Squibb 222
9.3.5 Anthera 223
9.3.6 ImmuPharma 225
9.3.7 Merck Serono 227
9.3.8 AstraZeneca 228
9.3.9 Pfizer 230

10 Market Outlook 232
10.1 Global Markets 232
10.1.1 Forecast 232
10.1.2 Drivers and Barriers – Global Issues 240
10.2 US 242
10.2.1 Forecast 242
10.2.2 Key Events 247
10.2.3 Drivers and Barriers 247
10.3 France 249
10.3.1 Forecast 249
10.3.2 Key Events 254
10.3.3 Drivers and Barriers 254
10.4 Germany 256
10.4.1 Forecast 256
10.4.2 Key Events 260
10.4.3 Drivers and Barriers 260
10.5 Italy 261
10.5.1 Forecast 261
10.5.2 Key Events 266
10.5.3 Drivers and Barriers 266
10.6 Spain 267
10.6.1 Forecast 267
10.6.2 Key Events 272
10.6.3 Drivers and Barriers 272
10.7 UK 273
10.7.1 Forecast 273
10.7.2 Key Events 278
10.7.3 Drivers and Barriers 278
10.8 Japan 279
10.8.1 Forecast 279
10.8.2 Key Events 284
10.8.3 Drivers and Barriers 284

11 Appendix 286
11.1 Bibliography 286
11.2 Abbreviations 304
11.3 Methodology 309
11.4 Forecasting Methodology 309
11.4.1 Diagnosed SLE and LN Patients 309
11.4.2 Percent Drug-Treated Patients 310
11.4.3 Drugs Included in Each Therapeutic Class 310
11.4.4 Launch and Patent Expiry Dates 310
11.4.5 General Pricing Assumptions 311
11.4.6 Individual Drug Assumptions 312
11.4.7 Generic Erosion 315
11.4.8 Pricing of Pipeline Agents 316
11.5 Physicians and Specialists Included in this Study 317
11.6 Primary Research – Prescriber Survey 319
11.7 About the Authors 320
11.7.1 Analysts 320
11.7.2 Epidemiologist 321
11.7.3 Global Head of Healthcare 321
11.8 About GlobalData 322
11.9 Disclaimer 322